{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:18:45Z","timestamp":1792700325194,"version":"4.5.0"},"reference-count":29,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2008,9,22]],"date-time":"2008-09-22T00:00:00Z","timestamp":1222041600000},"content-version":"vor","delay-in-days":2244,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Allergy Immunology"],"published-print":{"date-parts":[[2002,8]]},"abstract":"<jats:p>H<jats:sub>1<\/jats:sub>\u2010receptor antagonists are considered central to the treatment of atopic dermatitis (AD)\u2010associated pruritus and are widely used in the treatment of AD despite a lack of double\u2010blind, randomized clinical trials. In this study we analyzed the effects of the long\u2010term use of cetirizine on the severity, natural history, and treatment of AD. In the prospective, multi\u2010country, double\u2010blind, randomized, placebo\u2010controlled Early Treatment of the Atopic Child (ETAC<jats:sup>\u2122<\/jats:sup>) study, 817 infants (12\u201324\u2003months of age) who suffered from AD at study entry and with a history of atopic disease in a parent or sibling were treated for 18\u2003months with either cetirizine (0.25\u2003mg\/kg) or placebo twice daily. All concomitant medications for the treatment of AD were allowed but had to be recorded by the investigator in the case report form; the concomitant use of H<jats:sub>1<\/jats:sub>\u2010antihistamines was discouraged. The primary end\u2010point for efficacy was the onset of asthma. Secondary parameters of efficacy, however, were the consumption of concomitant medications for AD (topical and systemic treatment) and the severity of symptoms related to AD, which was rated with the AD scale, SCORAD. The severity of AD, as measured by SCORAD, decreased significantly (p &lt;\u20030.001) over the study period (18\u2003months) in both groups. Other oral H<jats:sub>1<\/jats:sub>\u2010antihistamines were significantly more often used in the placebo group than in the cetirizine group (24.9% vs. 18.6%, p = 0.03). The number of infants who developed urticaria during the study period was significantly lower with cetirizine treatment (placebo group: 16.2%; cetirizine group: 5.8%; p &lt;\u20030.001). For the treatment of AD, mild topical corticosteroids (class I, e.g. hydrocortisone) were used in 41.6% of the patients (placebo group 41.6%, cetirizine group 41.7%) and moderate\u2010to\u2010potent topical corticosteroids (class II, III, IV) in 55.0% (respectively 56.4% and 53.5%). The duration of the use of topical moderate\u2010to\u2010potent corticosteroids differed between the cetirizine group and the placebo group (mean percentage of days: placebo 25.2, median 2.4; cetirizine mean 18.8, median 0.95 p = 0.067, Mann\u2013Whitney test, not statistically significant). In sub\u2010groups of infants with a SCORAD of \u2265\u200a25, this cortico\u2010sparing effect was statistically significant (placebo 35.1 vs. 25.8 in the cetirizine group; p = 0.014, Mann\u2013Whitney test). In conclusion, in view of the proven safety of cetirizine, the use of this drug might help to reduce the duration and the amount of moderate\u2010to\u2010strong topical corticosteroids used in the treatment of infants and children with AD. However, further studies designed with the primary end\u2010point of AD are clearly indicated to confirm the benefits of the use of H<jats:sub>1<\/jats:sub>\u2010antihistamines in the management of AD.<\/jats:p>","DOI":"10.1034\/j.1399-3038.2002.01047.x","type":"journal-article","created":{"date-parts":[[2003,3,12]],"date-time":"2003-03-12T16:02:00Z","timestamp":1047484920000},"page":"278-286","source":"Crossref","is-referenced-by-count":144,"title":["Long\u2010term treatment with cetirizine of infants with atopic dermatitis: A multi\u2010country, double\u2010blind, randomized, placebo\u2010controlled trial (the ETAC<sup>\u2122<\/sup>trial) over 18\u2003months"],"prefix":"10.1111","volume":"13","author":[{"given":"Thomas L.","family":"Diepgen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,9,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.2340\/00015555924447"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511545771.009"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"issue":"42","key":"e_1_2_6_5_2","first-page":"26","article-title":"The natural history of childhood eczema","volume":"129","author":"Williams HC","year":"1993","journal-title":"Br J Dermatol"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70096-C"},{"key":"e_1_2_6_7_2","first-page":"4","article-title":"Receptor effects of cetirizine","volume":"59","author":"Snyder SH","year":"1987","journal-title":"Ann Allergy"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(05)80242-8"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/030006058901700103"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199040050-00009"},{"key":"e_1_2_6_11_2","first-page":"964","article-title":"Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge","volume":"262","author":"Charlesworth EN","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000237249"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(95)70324-1"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(92)90074-C"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.1998.tb00356.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70389-1"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1159\/000247298"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.1997.tb00139.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3038.1997.tb00157.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1067\/mai.2001.113866"},{"issue":"4","key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1399-3038.1993.tb00339.x","article-title":"A placebo\u2010contolled trial of cetirizine in seasonal allergic rhino\u2010conjunctivitis in children aged 6\u201312 years","volume":"4","author":"Masi M","year":"1993","journal-title":"Pediatr Allergy Immunol"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63462-X"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00045391-199905000-00005"},{"key":"e_1_2_6_24_2","first-page":"348","article-title":"Efficacy and safety of cetirizine therapy in perennial allergic rhinitis","volume":"68","author":"Mansmann HC","year":"1992","journal-title":"Ann Allergy"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(05)80246-5"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)90233-3"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1990.tb14732.x"},{"key":"e_1_2_6_28_2","first-page":"117","article-title":"Double\u2010blind study of ceterizine in atopic eczema in children","volume":"73","author":"La Rosa M","year":"1994","journal-title":"Ann Allergy"},{"key":"e_1_2_6_29_2","first-page":"127","article-title":"Dose ranging study: Cetirizine in the treatment of atopic dermatitis in adults","volume":"70","author":"Hannuksela M","year":"1993","journal-title":"Ann Allergy"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(05)80093-4"}],"container-title":["Pediatric Allergy and Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-3038.2002.01047.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1034%2Fj.1399-3038.2002.01047.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1034\/j.1399-3038.2002.01047.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,7]],"date-time":"2024-01-07T16:13:51Z","timestamp":1704644031000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1034\/j.1399-3038.2002.01047.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,8]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,8]]}},"alternative-id":["10.1034\/j.1399-3038.2002.01047.x"],"URL":"https:\/\/doi.org\/10.1034\/j.1399-3038.2002.01047.x","archive":["Portico"],"relation":{},"ISSN":["0905-6157","1399-3038"],"issn-type":[{"value":"0905-6157","type":"print"},{"value":"1399-3038","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,8]]}}}